(Q37258787)

19 August 2017

1 reference

title

Vasopressin and vasopressin antagonists in heart failure and hyponatremia (English)

1 reference

19 August 2017

0 references

0 references

4

Mihai Gheorghiade

1 reference

19 August 2017

2

Gerasimos Filippatos

1 reference

19 August 2017

1

Dimitrios Farmakis

1 reference

19 August 2017

author name string

Dimitrios T Kremastinos

series ordinal

3

1 reference

19 August 2017

publication date

1 June 2008

1 reference

Current heart failure reports

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

91-96

1 reference

Risk stratification after hospitalization for decompensated heart failure

19 August 2017

cites work

1 reference

12 December 2020

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

12 December 2020

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

1 reference

12 December 2020

OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

1 reference

12 December 2020

A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure

1 reference

12 December 2020

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

1 reference

12 December 2020

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

1 reference

12 December 2020

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure

1 reference

12 December 2020

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

1 reference

12 December 2020

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist

1 reference

12 December 2020

A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

1 reference

12 December 2020

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

1 reference

12 December 2020

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

1 reference

12 December 2020

Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].

1 reference

12 December 2020

Congestion in acute heart failure syndromes: an essential target of evaluation and treatment

1 reference

12 December 2020

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction

1 reference

12 December 2020

Acute heart failure syndromes: current state and framework for future research

1 reference

12 December 2020

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

1 reference

12 December 2020

Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial

1 reference

12 December 2020

Hyponatremia treatment guidelines 2007: expert panel recommendations

1 reference

12 December 2020

Lixivaptan (American Home Products).

1 reference

12 December 2020

Correlates of major complications or death in patients admitted to the hospital with congestive heart failure

1 reference

12 December 2020

Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

1 reference

12 December 2020

Vasopressin: a new target for the treatment of heart failure

1 reference

12 December 2020

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

12 December 2020

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

1 reference

12 December 2020

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

12 December 2020

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

1 reference

12 December 2020

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

1 reference

12 December 2020

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

1 reference

12 December 2020

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

12 December 2020

Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007.

1 reference

12 December 2020

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

12 December 2020

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs

1 reference

12 December 2020

Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure

1 reference

12 December 2020

Hyponatremia in patients with heart failure

1 reference

12 December 2020

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

12 December 2020

Hyponatremia: current treatment strategies and the role of vasopressin antagonists

1 reference

12 December 2020

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

1 reference

12 December 2020

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

12 December 2020

10.1007/S11897-008-0015-Z

Identifiers

DOI

1 reference

release_gsogtvknvraunlemiq7tbuxsc4

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gsogtvknvraunlemiq7tbuxsc4

24 November 2022

mapped directly with Wikidata item

1 reference